We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) announced that Health Canada has approved Ozempic (semaglutide injection) to improve glycemic control in adults with type II diabetes mellitus, when metformin is not tolerated or contraindicated. Ozempic, a once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist, can also be used together with other antidiabetic drugs when diet and exercise do not achieve adequate glycemic control.
Shares of the company have rallied 52.4% compared with the industry’s gain of 16.8% in the past year.
The approval of Ozempic was based on results from the phase III SUSTAIN study. The results showed that people with type II diabetes, who are treated with once-weekly semaglutide, experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo.
In December 2017, the FDA approved Ozempic once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. European regulatory authorities also adopted a positive opinion, recommending marketing authorization for Ozempicon Dec 15.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, its key pipeline candidate includes nonacog beta pegol.
The approval of the drug will give a boost to the company’s revenues.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes
Novo Nordisk (NVO - Free Report) announced that Health Canada has approved Ozempic (semaglutide injection) to improve glycemic control in adults with type II diabetes mellitus, when metformin is not tolerated or contraindicated. Ozempic, a once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist, can also be used together with other antidiabetic drugs when diet and exercise do not achieve adequate glycemic control.
Shares of the company have rallied 52.4% compared with the industry’s gain of 16.8% in the past year.
The approval of Ozempic was based on results from the phase III SUSTAIN study. The results showed that people with type II diabetes, who are treated with once-weekly semaglutide, experienced statistically significant and sustained blood glucose control compared with Merck’s (MRK - Free Report) Januvia (sitagliptin), Astrazeneca’s (AZN - Free Report) once-weekly Bydureon (exenatide extended-release), Sanofi’s (SNY - Free Report) Lantus (insulin glargine) and placebo.
In December 2017, the FDA approved Ozempic once-daily pre-filled pen to improve glycaemic control in type II diabetes patients. European regulatory authorities also adopted a positive opinion, recommending marketing authorization for Ozempicon Dec 15.
Additionally, Novo Nordisk is making efforts to develop new treatments for diabetes, which is its core area of expertise. In September 2017, the company received approval for its fast acting insulin aspart, Fiasp. Other than semaglutide, its key pipeline candidate includes nonacog beta pegol.
The approval of the drug will give a boost to the company’s revenues.
Novo Nordisk A/S Price
Novo Nordisk A/S Price | Novo Nordisk A/S Quote
Zacks Rank
Novo Nordisk carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>